Jefferies Group’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Jefferies Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$2.91M	Hold	360,200	–	–	0.02%	483
2022 Q2	$2.71M	Hold	360,200	–	–	0.02%	522
2022 Q1	$3.38M	Sell	360,200 -727,300	-67%	-$6.07M	0.02%	508
2021 Q4	$8.71M	Buy	1,087,500 +100,000	+10%	+$903K	0.05%	311
2021 Q3	$9.6M	Hold	987,500	–	–	0.07%	272
2021 Q2	$9.8M	Hold	987,500	–	–	0.06%	279
2021 Q1	$11.4M	Sell	987,500 -211,600	-18%	-$2.43M	0.1%	170
2020 Q4	$11.6M	Buy	1,199,100 +793,300	+195%	+$7.6M	0.09%	187
2020 Q3	$3.66M	Hold	405,800	–	–	0.04%	363
2020 Q2	$5M	Buy	405,800 +119,200	+42%	+$1.35M	0.06%	274
2020 Q1	$2.57M	Hold	286,600	–	–	0.03%	559
2019 Q4	$2.81M	Buy	+286,600	New	+$2.56M	0.02%	845
2019 Q3	–	Sell	-22,500	Closed	-$208K	–	3040
2019 Q2	$208K	Sell	22,500 -77,500	-78%	-$934K	﹤0.01%	2120
2019 Q1	$1.57M	Sell	100,000 -17,100	-15%	-$302K	0.01%	1039
2018 Q4	$1.81M	Buy	117,100 +100,000	+585%	+$2.05M	0.01%	867
2018 Q3	$368K	Sell	17,100 -140,400	-89%	-$3.26M	﹤0.01%	1768
2018 Q2	$3.83M	Buy	157,500 +87,500	+125%	+$1.78M	0.02%	608
2018 Q1	$1.2M	Buy	+70,000	New	+$1.37M	0.01%	1121
2017 Q3	–	Sell	-100,000	Closed	-$3.32M	–	2612
2017 Q2	$3.32M	Buy	+100,000	New	+$3.1M	0.02%	722
2016 Q4	–	Sell	-28,400	Closed	-$1.31M	–	2473
2016 Q3	$1.31M	Buy	+28,400	New	+$1.48M	0.01%	1151
2016 Q1	–	Sell	-234,800	Closed	-$15.4M	–	2550
2015 Q4	$15.4M	Buy	234,800 +184,800	+370%	+$11.4M	0.09%	180
2015 Q3	$2.82M	Buy	50,000 +43,200	+635%	+$2.8M	0.02%	736
2015 Q2	$402K	Buy	+6,800	New	+$419K	﹤0.01%	1665
2014 Q2	–	Sell	-221,100	Closed	-$11.7M	–	2374
2014 Q1	$11.7M	Buy	221,100 +44,800	+25%	+$2.07M	0.11%	149
2013 Q4	$7.07M	Buy	+176,300	New	+$6.94M	0.04%	236

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $16.3B AUM 54.64% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.8B AUM 42.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $20.7B AUM 58.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $21.3B AUM 44.31% 1-Year Est. Return

Jefferies Group's TEVA Position: Q3 2022 in Review

Jefferies Group reduced its Teva Pharmaceutical Industries Limited (TEVA) stake by 6.2% in Q3 2022, selling an estimated $150K and leaving 258,664 shares worth $2.09M. The position accounts for 0.02% of the portfolio, ranked #591.

Jefferies Group first reported a position in TEVA in Q3 2013 and has held it in 32 quarters since. The position peaked at $72.6M in Q1 2015. 431 funds tracked by Wall St. Rank hold TEVA as of Q3 2022.

Jefferies Group held 258,664 shares of Teva Pharmaceutical Industries Limited worth $2.09M as of Q3 2022.
Jefferies Group sold 16,965 Teva Pharmaceutical Industries Limited shares in Q3 2022, an estimated $150K.
Teva Pharmaceutical Industries Limited made up 0.02% of Jefferies Group's portfolio in Q3 2022, its #591 holding.
Jefferies Group first reported a position in Teva Pharmaceutical Industries Limited in Q3 2013 and has held it in 32 quarters since.
Jefferies Group's Teva Pharmaceutical Industries Limited position peaked at $72.6M in Q1 2015.
431 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.